Methylprednisolone Completed Phase 2 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00623766Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases